ãã€ãªå»è¬åäŒæ¥ã§ãã ProQR Therapeutics NV ã¯ãéºäŒæ§çŸæ£ã®æ²»çã®ããã® RNA ããŒã¹ã®æ²»çè¬ã®çºèŠãšéçºã«åãçµãã§ããŸããå瀟ã¯äž»ã«ãã¬ãŒããŒå
倩æ§é»å
é 10 çã®æ²»çè¬ãšããŠãã§ãŒãº II/III ã®ã€ã«ãããŒã·ã§ã³è©Šéšäžã®ã»ããã¡ã«ã»ã³ãã¢ãã·ã£ãŒçå矀ã¿ã€ã 2 ããã³éçåæ§ç¶²èè²çŽ å€æ§çã®æ²»çè¬ãšããŠãã§ãŒãº I/II ã®ã¹ãã©è©Šéšäžã® QR-421aãåžžæè²äœåªæ§ç¶²èè²çŽ å€æ§çã®æ²»çè¬ãšããŠãã§ãŒãº I/II ã®ãªãŒãã©è©Šéšäžã® QR-1123ãããã³ããã¯ã¹è§èå
ç®ãžã¹ãããã£ãŒã®æ²»çè¬ãšããŠåã®èšåºè©Šéšäžã® QR-504a ãéçºããŠããŸããå瀟ã¯ãèèããã³ç¥çµç³»ã®éºäŒæ§çŸæ£ã«å¯Ÿããæœåšçãªæ°è¬ã®çºèŠãéçºãããã³åååã«é¢ããŠãã©ãããŠã倧åŠå»çã»ã³ã¿ãŒãInserm Transfert SAãIonis Pharmaceuticals, Inc.ãã©ã€ãã³å€§åŠå»çã»ã³ã¿ãŒãããã³ ProQR Therapeutics VIII BV ãšã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããProQR Therapeutics NV 㯠2012 幎ã«èšç«ããããªã©ã³ãã®ã©ã€ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã